The EEF2K Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the human EEF2K gene in Jurkat T lymphocytes. This CRISPR/Cas9-mediated gene disruption abolishes EEF2K protein expression, providing a loss-of-function model for investigating eukaryotic elongation factor 2 kinase function. The polyclonal format presents a heterogeneous knockout background suitable for bulk functional assays while avoiding clonal selection biases.
Jurkat cells are an immortalized human T lymphocyte cell line derived from the peripheral blood of a 14-year-old male with acute T cell leukemia. They serve as a widely used model for studies of T cell receptor signaling, apoptosis, and leukemogenesis, offering a robust platform for examining oncogenic processes and therapeutic interventions in a human T cell context.
EEF2K encodes a calcium/calmodulin-dependent kinase that phosphorylates eukaryotic elongation factor 2 (EEF2) to inhibit ribosomal translocation during protein synthesis elongation. The kinase is activated by Ca2+/calmodulin and regulated downstream of mTORC1, AMPK, PKA, and S6K, integrating nutrient, energy, and stress signals. EEF2K interacts directly with calmodulin and EEF2, and its activity is modulated by AMPK phosphorylation and mTORC1-dependent inputs. Through phosphorylation of EEF2, EEF2K links cellular metabolic status to translation efficiency, thereby influencing cell cycle progression, apoptosis, and autophagy.
In Jurkat T lymphocytes, EEF2K knockout removes a critical regulatory node connecting energy and nutrient sensing to translational control, a process essential for activated T cell proliferation and leukemic growth. This disruption allows researchers to dissect how defects in translational elongation affect malignant cell survival under metabolic stress, autophagy, and apoptotic signaling, yielding insights into the pathogenesis of acute T cell leukemia and potential therapeutic vulnerabilities.
These polyclonal knockout cells are amenable to assays including Western blotting for EEF2K and phospho-EEF2, flow cytometry-based cell cycle and apoptosis analysis, ATP metabolic assays, RT-qPCR for downstream gene expression, puromycin incorporation protein synthesis measurements, migration assays, and drug sensitivity testing. Applications encompass functional elucidation of EEF2K in T lymphocyte biology, investigation of translational control in leukemia, autophagy and apoptosis mechanisms, stress response pathways, and target validation. For more information, please contact Ascent Research.
